Business Model Breakdown
How Vyne Therapeutics Inc Makes Money
VYNE
Market Cap
$20M
Annual Revenue
$570,000
Profit Margin
-4646.1%
Employees
13
The Short Version
Vyne Therapeutics Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated inflammatory diseases. However, its current business model is primarily centered around a strategic merger with Yarrow Bioscience as a means of corporate survival. In this transaction, Vyne effectively becomes a shell that transfers its remaining assets and cash in exchange for a highly diluted stake in Yarrow's pipeline. Any future revenue or value generation will be contingent upon the success of Yarrow's lead candidate, YB-101, for Graves' disease and thyroid eye disease, rather than Vyne's original therapeutic programs.
Where the Revenue Comes From
Minimal existing revenue (TTM $524,000, likely from minor licensing or prior product sales)
Future potential revenue from Yarrow Bioscience's pipeline (post-merger)
Who buys: N/A (primarily a clinical-stage biotech; future customers would be patients of Yarrow's potential commercial products)
Why It Works (Competitive Advantages)
- ✔None for current VYNE (original pipeline failing or being de-emphasized).
- ✔Potential IP of Yarrow's YB-101 (only relevant for the highly diluted post-merger entity).
Economic Moat: None
What Our Analysis Says
DVR Score as of April 20, 2026
Vyne Therapeutics Inc. (VYNE) presents an extremely high-risk, near-zero reward profile for existing shareholders, solidifying its precarious position since the last analysis. The primary concern is the impending merger with Yarrow Bioscience, where current VYNE shareholders are expected to own only 3% of the combined entity, ensuring near-total value destruction through massive dilution. This prospect is further cemented by the recent S-4 filing. Additionally, a new clinical trial (Repibresib gel) has failed. The company reports substantial and increasing losses, with TTM net income at negative $33.67 million and a dire net margin. While short-term liquidity (Current/Quick Ratio of 7.60) is robust, it is being rapidly consumed. Analyst sentiment is 'Reduce,' and insider activity shows no conviction. The path to 10x growth for existing shareholders is virtually nonexistent under these conditions.